09/08/2026
An amazing announcement just recently is a major step forward for pancreatic cancer patients! The FDA has approved Rasonque (daraxonrasib)—the first targeted therapy of its class for metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer.
This once-daily tablet targets RAS, a key driver of tumor growth in the majority of pancreatic adenocarcinomas, offering a new treatment option for adults with metastatic disease who have already received systemic therapy or are not candidates for multiagent treatment.
Most significantly, in a clinical trial of 500 patients, Rasonque more than doubled median overall survival—from 6.7 months with standard chemotherapy to 13.2 months.
For a cancer that has historically been difficult to detect and treat, this approval represents more than a new medicine. It represents progress, hope and more time for patients and their families.
The FDA’s decision—made 6.5 months ahead of the user fee deadline—also underscores the importance of accelerating access to innovative treatments for serious and life-threatening diseases.
There is still much work to do in pancreatic cancer, particularly around early detection, improved treatment options, and access to care. But today, we recognize an important milestone.
For pancreatic cancer patients and families, every month matters. Every treatment option matters. Every breakthrough matters.
Read the full announcement here: https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer
